Antiangiogenic therapy for glioblastoma.
Antiangiogenic therapy for glioblastoma.
复制标题
DOI：
10.1097/ppo.0b013e3182431c6f
复制
发表时间：
2012-01
期刊：
影响因子：
--
通讯作者：
Batchelor TT
中科院分区：
文献类型：
--
作者：
Gerstner ER;Batchelor TT
由于表达多种促血管生成因子，胶质母细胞瘤是血管最多的肿瘤之一。正在开发针对血管生成的新药物方案，以试图阻止肿瘤生长。特别是，血管内皮生长因子（VEGF）途径一直是主要的药物靶点。抗 VEGF 药物的初步结果令人鼓舞，据报道无进展生存期延长。此外，抗 VEGF 药物的抗渗透作用通过减少皮质类固醇依赖性对肿瘤成像和患者生活质量产生重要影响。不幸的是，抗 VEGF 治疗的反应是短暂的，大多数患者最终会复发，因此需要更多的工作来了解肿瘤逃逸的机制。
Glioblastomas are among the most vascular tumors due to the expression of a variety of pro-angiogenic factors. New drug regimens are being developed to target angiogenesis in an attempt to arrest tumor growth. In particular, the vascular endothelial growth factor (VEGF) pathway has been a prime drug target. Preliminary results with anti-VEGF agents have been promising with prolonged progression-free survival reported. In addition, the anti-permeability effects of anti-VEGF agents have important consequences for tumor imaging and for patient quality of life by decreasing corticosteroid dependence. Unfortunately, the response to anti-VEGF therapy is transient and the majority of patients eventually relapse so more work is needed to understand mechanisms of tumor escape.